5 minute read
May 29, 2023

Navoximod: An Early Heme-Binding Inhibitor of the Once Red-Hot Immunotherapy Target, IDO1

navoximod

oral IDO1 inhibitor Ph. I completed (50-800 mg) for cancer from phenylimidazole + SBDD JPET, April 14, 2023 NewLink Genetics / Genentech

drughunter.com
Drug Hunter Team

Indoleamine 2,3-dioxygenase 1 (IDO1) is an extrahepatic tryptophan-metabolizing enzyme which is believed to contribute to the evasion of the immune system by tumors , making it an attractive target for cancer immunotherapy, especially in combination with immune [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in